Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2023-01-10 Regulatory Filings
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2023-01-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 27, 2022. It announces the filing of a Form S-4 Registration Statement related to a proposed business combination with AEON Biopharma, Inc. The document includes a press release as Exhibit 99.1 and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full report. The content is typical of a regulatory filing providing updates on corporate events and communications, not a full financial report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4617 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-12-27 English
425 Filing
Regulatory Filings
2022-12-27 English
FORM S-4
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy statement and prospectus related to a business combination (merger) between Priveterra Acquisition Corp. and AEON Biopharma, Inc. It details the terms of the merger, the issuance of shares, and the special meeting of stockholders to approve the transaction. The content focuses on merger proposals, share conversions, and related corporate actions. This type of filing is specifically related to merger and acquisition activity, including tender offers and proxy statements for shareholder approval of such transactions. Therefore, the document fits best under the 'Merger & Acquisition' category (Code: MA). The document length and detail confirm it is the filing itself, not just an announcement or summary.
2022-12-24 English
Regulatory Filings 2022
Regulatory Filings
2022-12-23 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a preliminary proxy statement on Schedule 14A. It discusses updates to the proxy statement and addresses regulatory comments. The document does not contain financial statements or detailed financial data, nor is it the proxy statement itself. It is a regulatory correspondence related to the proxy statement filing. Given the nature of the document as a response letter to SEC comments on a proxy statement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence that does not fit other specific categories.
2022-12-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.